Jul. 27 at 7:50 AM
$ABP $ABP received single digit million dollars of upfront payment and is eligible for net sales milestone payments of up to
$1.75 billion and development milestone payments of up to
$4.0 million, Abpro also received an equity investment from Celltrion in connection with this agreement. Abpro is responsible for certain in vitro pre-clinical work, and Celltrion is responsible for in vivo preclinical work, CMC, clinical development and commercialization on a worldwide basis.
How can you not be bullish at current evaluations? What's the missing piece here?